Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 57-65

  Soares, Claudio N ^a   Fayyad, Rana S ^b   Guico Pabia, Christine J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b PFIZER INC   (United States)

Author keywords

Desvenlafaxine; Major depressive disorder; Predictive value of tests; Prognosis; Second generation antidepressants; Time factors; Treatment outcome

Indexed keywords

DESVENLAFAXINE;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891737669     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000049     Document Type: Article

References (41)

1. Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. Available at: http://www.psychiatryonline.com/pracGuide/pracGuideTopic-7.aspx. Accessed October 6, 2013.
2. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71(suppl E1):e08-e017.
3. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(suppl E1):e04-e15.
4. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med. 2011;155:772-785.
5. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
6. Milea D, Guelfucci F, Bent-Ennakhil N, et al. Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clin Ther. 2010;32:2057-2072.
7. Polsky D, Onesirosan P, Bauer MS, et al. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans. J Clin Psychiatry. 2002;63:156-164.
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry. 2006;163:1905-1917.
9. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
10. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354: 1243-1252.
11. Trivedi MH, Lin EH, Katon WJ. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectr. 2007;12:1-27.
12. Burra TA, Chen E, McIntyre RS, et al. Predictors of self-reported antidepressant adherence. Behav Med. 2007;32:127-134.
13. Fortney JC, Pyne JM, Edlund MJ, et al. Reasons for antidepressant nonadherence among veterans treated in primary care clinics. J Clin Psychiatry. 2011;72:827-834.
14. Okuda A, Suzuki T, Kishi T, et al. Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin Neurosci. 2010;64:268-273.
15. de Diego-Adelino J, Portella MJ, Puigdemont D, et al. A short duration of untreated illness (DUI) improves response outcomes in first-depressive episodes. J Affect Disord. 2010;120:221-225.
16. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry. 2001;62(suppl 4):17-23.
17. Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006;26:56-60.
18. Taylor MJ. Rapid onset of true antidepressant action. Curr Psychiatry Rep. 2007;9:475-479.
19. Koran LM, Hamilton SH, Hertzman M, et al. Predicting response to fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1995;15:421-427.
20. Farabaugh A, Mischoulon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005;20:87-91.
21. Farabaugh A, Sonawalla S, Johnson DP, et al. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010;22:166-171.
22. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64:413-420.
23. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344-353.
24. Henkel V, Seemuller F, Obermeier M, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 2009;115:439-449.
25. Kok RM, van Baarsen C, Nolen WA, et al. Early response as predictor of final remission in elderly depressed patients. Int J Geriatr Psychiatry. 2009;24:1299-1303.
26. Lin CH, Lane HY, Chen CC, et al. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011;31:187-193.
27. Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14:144-154.
28. Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009;31(Pt 1):1405-1423.
29. Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011;31:569-576.
30. Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:1877-1890.
31. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243-253.
32. Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50 mg/d in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013;19(1):5-14.
33. Liebowitz MR, Tourian KA, Hwang E, et al. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry. 2013;13:94.
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
35. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976;217-222.
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
37. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000;113-115.
38. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull. 1982;18:69-77.
39. Gallop RJ. Determination and interpretation of the OOP for ROC's with PROC LOGISTIC. Proceedings of the NorthEast SAS Users Group. Baltimore, MD: NorthEast SAS Users Group; 2001;777-782.
40. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand. 1975;51:161-170.
41. Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1983-1989.